RESUMEN
CONTEXT: Rice Bran Arabinoxylan Compound (RBAC) is a trusted and proven immunomodulator made from a rice bran extract that has been enzymatically modified with an enzyme complex from the shiitake mushroom. OBJECTIVE: The study's primary objective was to identify the role of RBAC in supporting cancer therapies. DESIGN: The author designed an open study. PARTICIPANTS: Participants were 14 patients who are suffering from various type of malignancies. INTERVENTION: BRM4 capsules-a commercially available, proprietary RBAC supplement-were administered. OUTCOME MEASURES: The study measured circulating tumor cells (CTC) and tumor markers-the prostate-specific antigen (PSA) and cancer antigens 125 (CA125) 15-3 (CA15-3), and 27-29 (CA27-29) for the relevant malignancy. RESULTS: Twelve out of 14 participants completed the protocol, and two participants died during the study. Of the 12 participants completing the study, the CTC levels were reduced in 10, with a statistically significant difference between the testing at baseline and postintervention (P = .0047). The tumor markers of various malignancies decreased for nine out the 12 participants, and one participant experienced remission. CONCLUSIONS: The results suggest that the product can be an effective immunomodulator that can complement conventional cancer treatment.